Two of the most researched fat loss peptides in 2026 are Retatrutide and Tirzepatide. Both are incretin-based peptides targeting GLP-1 receptors — but one goes significantly further.
Mechanism: Triple vs Dual Agonist
Tirzepatide — Dual GIP/GLP-1 Agonist
Tirzepatide targets two receptors: GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1). This dual mechanism improves insulin sensitivity, reduces appetite, slows gastric emptying, and promotes fat oxidation.
Retatrutide — Triple GIP/GLP-1/Glucagon Agonist
Retatrutide adds a third target: the glucagon receptor. Glucagon receptor agonism directly increases energy expenditure and hepatic fat oxidation — going beyond appetite suppression to actively burn stored fat.
Clinical Results Comparison
Tirzepatide: Phase 3 SURMOUNT trials showed ~15–20% mean body weight reduction over 72 weeks.
Retatrutide: Phase 2 trials showed 17–24% mean body weight reduction over 48 weeks — with a shorter trial duration.
Dosage Comparison
Tirzepatide: 2.5–15 mg/week | Half-life: ~5 days | Price: ₹5,999/20mg
Retatrutide: 2–12 mg/week | Half-life: ~6 days | Price: ₹4,999/10mg
Which Should You Choose?
Choose Retatrutide if: Maximum fat loss efficacy is the priority. The triple agonist mechanism and clinical data make it the more potent option.
Choose Tirzepatide if: You want a dual agonist with Phase 3 clinical data and a well-established dosing protocol.
Both are available at Peptide Central's fat loss peptide category with 98%+ purity, COA included, and pan-India COD delivery.